Page last updated: 2024-08-23

raloxifene hydrochloride and Hangman Fracture

raloxifene hydrochloride has been researched along with Hangman Fracture in 106 studies

Research

Studies (106)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	6 (5.66)	18.2507
2000's	79 (74.53)	29.6817
2010's	15 (14.15)	24.3611
2020's	6 (5.66)	2.80

Authors

Authors	Studies
Baek, KH; Ha, J; Jeong, C; Kang, MI; Kim, J; Kim, MK; Kwon, HS; Lim, Y; Song, KH	1
Fukunaga, M; Hagino, H; Mori, S; Nakamura, T; Ohta, H; Orimo, H; Shiraki, M; Soen, S; Sone, T; Tanaka, S; Uemura, Y	1
Jenal, M; Ma, N; Moshi, MR; Nicolopoulos, K; Stringer, D; Vreugdenburg, T	1
Chen, D; Huang, X; Jin, Z; Liu, Q; Ma, T; Ye, Z	1
Hagino, H; Mori, S; Nakamura, T; Ohta, H; Sone, T; Uemura, Y	1
Hara, T; Hijikata, Y; Matsubara, Y; Watanabe, N	1
Balasubramanian, A; Cooper, C; Cummings, SR; Feudjo, MT; Guo, H; Sprafka, JM; Watts, NB; Yusuf, AA; Zhou, J	1
Fukunaga, M; Hagino, H; Miyazaki, T; Mori, S; Nakamura, T; Ohta, H; Orimo, H; Shiraki, M; Soen, S; Sone, T; Sugimoto, T; Taguchi, A; Tanaka, S; Tsukiyama, M; Uemura, Y	1
D'Amelio, P; Isaia, GC	1
Chines, A; Kaufman, JM; Palacios, S; Silverman, S; Sutradhar, S	1
Ohashi, S; Ono, K; Tanaka, S	1
Reid, IR	1
Chen, YC; Cheng, TT; Lin, WC; Lui, CC; Su, FM	1
Ohta, H	2
Abrahamsen, B; Eiken, P; Roerholt, C	1
Bobula, J; Lips, P; van Schoor, NM; Yu, H	1
Bouxsein, ML; Chen, P; Delmas, PD; Glass, EV; Kallmes, DF; Mitlak, BH	1
Barrett-Connor, E; Cox, DA; Grady, D; Mitlak, B; Mosca, L; Song, J	1
Krege, JH; Sontag, A; Wan, X	1
Becker, C	1
Nakamura, T; Sakai, A	1
Iwamoto, J	1
Barker, C; Brixen, K; del Pino, J; Farrerons, J; Keen, R; Lyritis, G; Marin, F; Nickelsen, TN; Pfeifer, M	1
Johansson, H; Kanis, JA; McCloskey, EV; Oden, A	1
Thiebaud, D	1
Iba, K; Takada, J; Yamashita, T	1
Hadji, P	1
Gluck, O; Maricic, M	2
Adachi, JD; Black, DM; Delmas, PD; Eastell, R; Ensrud, KE; Genant, HK; Gennari, C; Harper, KD; Harris, ST; Pols, HA; Recker, RR; Reginster, JY; Sarkar, S; Wu, W	1
Adachi, JD; Crans, GG; Fuerst, T; Genant, HK; Harper, KD; Lu, Y; Siris, E; Wong, M	1
Begerow, B; Hinz, C; Minne, HW; Pfeifer, M; Pollähne, W	1
Begerow, B; Minne, HW; Pfeifer, M; Pollähne, W	1
Black, DM; Downs, RW; Fuerst, T; Johnell, O; Kanis, JA; Pavo, I; Sarkar, S; Secrest, RJ	1
Lippuner, K	1
Adachi, JD; Crans, GG; Delmas, PD; Genant, HK; Siris, E; Stock, JL; Wong, M	1
Agnusdei, D; Bruyere, O; Collette, J; Henrotin, Y; Reginster, JY; Sarkar, S; Zegels, B	1
Itabashi, A	2
Hosoi, T	1
Crans, GG; Delmas, PD; Diez-Perez, A; Pinette, KV; Reginster, JY; Sarkar, S	1
Balogh, A; Black, DM; Johnell, O; Kanis, JA; Pavo, I; Poor, G; Sarkar, S; Zhou, C	1
Clarke, A; Layton, D; Shakir, SA; Wilton, LV	1
Delmas, PD; Kulkarni, PM; Plouffe, L; Silverman, SL; Stock, JL; Wong, M	1
Cauley, JA; Johnell, O; Kulkarni, PM; Stock, JL; Wong, M	1
Vlak, T	1
Ewing, S; Lips, P; Oleksik, AM; Shen, W; van Schoor, NM	1
Nakamura, T	2
Mori, S	1
Inaba, M	1
Cyaki, O	1
Sohen, S	1
Shintani, M	1
Borgström, F; Johnell, O; Jönsson, B; Kanis, JA; Oden, A; Sykes, D	2
Bartl, R	1
Blackwell, T; Cummings, SR; Ensrud, K; Grady, D; Henderson, VW; Krueger, K; Sarkar, S; Yaffe, K	1
Antoniucci, DM; Black, DM; Blackwell, T; Sellmeyer, DE; Vittinghoff, E	1
Cheung, AM; Grady, D; Litwack, S; Walsh, JM; Yang, D	1
Crans, GG; Delmas, PD; Diez-Perez, A; Pinette, KV; Seeman, E	1
Brown, SA; Rosen, CJ	1
Qu, Y; Stock, JL; Thiebaud, D; Wong, M	1
Barrett-Connor, E; Collins, P; Geiger, MJ; Grady, D; Kornitzer, M; McNabb, MA; Mosca, L; Wenger, NK	1
Stefanick, ML	1
Matsumoto, T	1
Pines, A	1
Roux, C	1
Barna, A; Bourgoin, M; Briot, K; Chapurlat, R; Christin-Maitre, S; Cortet, B; Costagliola, D; Diebolt, V; Dumarcet, N; Lacoin, F; Letombe, B; Nouyrigat, E; Oberlin, F; Orcel, P; Ravaud, P; Roux, C; Seret, P; Thomas, T; Veyries, ML; Vogel, JY; Yoldjian, I	1
Gold, DT; Silverman, SL	1
Agnusdei, D; Barrett-Connor, E; Cauley, JA; Ensrud, KE; Grady, D; Khaw, KT; Mosca, L; Stock, JL; Zhao, Q	1
Soen, S	1
Okano, H	1
Blackwell, T; Cummings, SR; Ensrud, KE; Ishani, A; Jamal, SA	1
Gärtner, R	1
Argueta, R; Caplan, RH; Knickerbocker, RK; Lufkin, EG; Nickelsen, T; Riggs, BL; Whitaker, MD	1
MacReady, N	1
Avioli, LV; Black, DM; Christiansen, C; Cohen, FJ; Cummings, SR; Delmas, PD; Eckert, S; Ensrud, KE; Ettinger, B; Genant, HK; Glüer, CC; Knickerbocker, RK; Krueger, K; Lips, P; Mitlak, BH; Nickelsen, T; Stakkestad, J; Zanchetta, JR	1
Feinberg, AW	1
Meunier, PJ; Vignot, E	1
Body, JJ; Sternon, J	1
Einhorn, TA	1
Becker-Brüser, W; Halbekath, J; Wille, H	1
Bravenboer, N; Compston, J; Lips, P; Oleksik, A; Ott, SM; Vedi, S	1
Cooper, C; Dawson, A; Kanis, J; Lips, P; Minshall, ME; Oleksik, A; Shen, W	1
Bashore, R	1
Rosenfeld, JA	1
Compston, JE	1
Harper, KD; Minshall, ME; Shen, W; Silverman, SL; Xie, S	1
Evans, MF; Hathirat, S	1
Black, DM; Harper, KD; Mitlak, BH; Sarkar, S; Stock, JL; Wong, M	1
Melton, LJ; Riggs, BL	1
Cauley, JA; Cummings, SR; Duong, T; Kenyon, E; Krueger, KA; Whitehead, M	1
Kruse, HP	1
Bjarnason, NH; Christiansen, C; Delmas, PD; Duong, T; Mitlak, B; Sarkar, S	1
Harper, K; Lips, P; Lu, Y; Oleksik, A; Ott, SM	1
Taga, M	1
Adachi, JD; Harper, KD; Maricic, M; Sarkar, S; Wong, M; Wu, W	1
MacIver, DW	1

Reviews

36 review(s) available for raloxifene hydrochloride and Hangman Fracture

Article	Year
The Clinical Effectiveness of Denosumab (Prolia®) for the Treatment of Osteoporosis in Postmenopausal Women, Compared to Bisphosphonates, Selective Estrogen Receptor Modulators (SERM), and Placebo: A Systematic Review and Network Meta-Analysis. Calcified tissue international, 2023, Volume: 112, Issue:6 Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Humans; Ibandronic Acid; Network Meta-Analysis; Osteoporosis; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Risedronic Acid; Selective Estrogen Receptor Modulators; Spinal Fractures; Treatment Outcome	2023
Minodronate in the treatment of osteoporosis: A systematic review and meta-analysis. Medicine, 2020, Oct-02, Volume: 99, Issue:40 Topics: Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Bone Density Conservation Agents; Case-Control Studies; Collagen Type I; Creatinine; Diphosphonates; Drug Therapy, Combination; Female; Humans; Imidazoles; Male; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid; Spinal Fractures; Tartrate-Resistant Acid Phosphatase; Treatment Outcome; Vitamin D	2020
Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3-5D. The Cochrane database of systematic reviews, 2021, Jul-07, Volume: 7 Topics: Antibodies, Monoclonal; Bias; Bone Density; Bone Density Conservation Agents; Denosumab; Female; Femur Neck; Fractures, Spontaneous; Hip; Humans; Indoles; Lumbar Vertebrae; Osteoporosis, Postmenopausal; Parathyroid Hormone-Related Protein; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Spinal Fractures; Teriparatide; Thiophenes; Watchful Waiting	2021
The use of raloxifene in osteoporosis treatment. Expert opinion on pharmacotherapy, 2013, Volume: 14, Issue:7 Topics: Bone Density Conservation Agents; Breast Neoplasms; Clinical Trials as Topic; Cost-Benefit Analysis; Female; Humans; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures	2013
[Anti-osteoporosis drugs based on the guidelines for the Prevention and Treatment of Osteoporosis (2011 edition) ]. Clinical calcium, 2014, Volume: 24, Issue:3 Topics: Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Cholecalciferol; Denosumab; Diphosphonates; Drug Therapy, Combination; Fractures, Spontaneous; Humans; Ibandronic Acid; Molecular Targeted Therapy; Osteoporosis; Practice Guidelines as Topic; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures; Teriparatide	2014
[Muscle and bone health as a risk factor of fall among the elderly. Role of raloxifene in the prevention of osteoporotic fractures]. Clinical calcium, 2008, Volume: 18, Issue:6 Topics: Bone Density Conservation Agents; Humans; Osteoporosis; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Spinal Fractures; Spine	2008
[Effects of SERMs on bone health. Efficacy of SERM for incidence of fractures in osteoporotic patients with lifestyle-related diseases]. Clinical calcium, 2010, Volume: 20, Issue:3 Topics: Adiponectin; beta Catenin; Diabetes Mellitus, Type 2; Female; Fractures, Spontaneous; Humans; Hyperlipidemias; Hypertension; Life Style; Meta-Analysis as Topic; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Signal Transduction; Spinal Fractures; Wnt Proteins	2010
[Effects of SERMs on bone health. Discrimination of SERMs from bisphosphonates in the treatment of postmenopausal osteoporosis]. Clinical calcium, 2010, Volume: 20, Issue:3 Topics: Biomarkers; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Spontaneous; Homocysteine; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Retrospective Studies; Selective Estrogen Receptor Modulators; Spinal Fractures	2010
A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX. Bone, 2010, Volume: 47, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Algorithms; Bone Density Conservation Agents; Female; Humans; Incidence; Middle Aged; Osteoporotic Fractures; Placebos; Proportional Hazards Models; Raloxifene Hydrochloride; Risk Factors; Spinal Fractures; Treatment Outcome	2010
[Diagnostic imaging of treatment in osteoporosis: SERM]. Clinical calcium, 2011, Volume: 21, Issue:7 Topics: Absorptiometry, Photon; Bone and Bones; Bone Density; Female; Hip Fractures; Humans; Indoles; Osteoporosis; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Spinal Fractures; Tomography, X-Ray Computed	2011
The evolution of selective estrogen receptor modulators in osteoporosis therapy. Climacteric : the journal of the International Menopause Society, 2012, Volume: 15, Issue:6 Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Endometrial Neoplasms; Female; Fractures, Bone; Hot Flashes; Humans; Indoles; Middle Aged; Osteoporosis, Postmenopausal; Pyrrolidines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures; Tetrahydronaphthalenes	2012
Raloxifene: recent information on skeletal and non-skeletal effects. Current opinion in rheumatology, 2002, Volume: 14, Issue:4 Topics: Bone and Bones; Bone Density; Breast Neoplasms; Cardiovascular Diseases; Female; Fractures, Spontaneous; Humans; Osteoporosis, Postmenopausal; Quality of Life; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Spinal Fractures; Uterus	2002
[Osteoporosis: prevention of bone loss and fractures]. MMW Fortschritte der Medizin, 2002, Nov-28, Volume: 144, Issue:48 Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Bone Diseases, Metabolic; Diagnosis, Differential; Exercise; Female; Fractures, Bone; Hip Fractures; Humans; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors; Spinal Fractures; Time Factors; Tomography, X-Ray Computed	2002
Medical treatment of vertebral osteoporosis. European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society, 2003, Volume: 12 Suppl 2 Topics: Aged; Calcitonin; Diphosphonates; Female; Humans; Incidence; Male; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Spinal Fractures	2003
[MORE study(raloxifene)]. Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 2 Topics: Biomarkers; Bone Density; Breast Neoplasms; Cardiovascular Diseases; Double-Blind Method; Female; Humans; Multicenter Studies as Topic; Osteocalcin; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Spinal Fractures; Treatment Outcome; Venous Thrombosis	2004
[Raloxifene hydrochloride]. Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 2 Topics: Arteriosclerosis; Bone Density; Bone Resorption; Breast Neoplasms; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Estrogen Antagonists; Estrogens; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures	2004
[Prevention of fractures with therapeutic agents for osteoporosis]. Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 2 Topics: Aged; Bone Density; Diphosphonates; Estrogen Receptor Modulators; Estrogen Replacement Therapy; Femoral Neck Fractures; Humans; Meta-Analysis as Topic; Osteoporosis; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Spinal Fractures	2004
[Compression vertebral fracture in osteoporosis--prevention and treatment]. Reumatizam, 2004, Volume: 51, Issue:2 Topics: Aged; Female; Fractures, Spontaneous; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Spinal Fractures	2004
[Bone quality in treatment with raroxifene ]. Clinical calcium, 2004, Volume: 14, Issue:5 Topics: Bone Density; Etidronic Acid; Evidence-Based Medicine; Femoral Neck Fractures; Humans; Meta-Analysis as Topic; Osteoporosis; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Regression Analysis; Reproducibility of Results; Risedronic Acid; Spinal Fractures; Testosterone	2004
[Contribution of bone quality to fracture risk]. Clinical calcium, 2004, Volume: 14, Issue:10 Topics: Bone and Bones; Bone Density; Bone Matrix; Bone Remodeling; Calcification, Physiologic; Controlled Clinical Trials as Topic; Female; Femoral Neck Fractures; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Spinal Fractures	2004
[SERM & bone metabolism: protective effects of SERM against fracture risk and its long-term beneficial effects]. Clinical calcium, 2004, Volume: 14, Issue:10 Topics: Bone Density; Elbow; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk; Risk Assessment; Selective Estrogen Receptor Modulators; Spinal Fractures; Time Factors	2004
[Relationship between changes in biochemical markers of bone turnover and prediction value of fracture risk]. Clinical calcium, 2004, Volume: 14, Issue:10 Topics: Biomarkers; Bone and Bones; Bone Density; Controlled Clinical Trials as Topic; Female; Humans; Osteocalcin; Osteoporosis, Postmenopausal; Predictive Value of Tests; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Spinal Fractures; Treatment Outcome	2004
[Defining the role of raloxifene as a therapeutic agent for postmenopausal osteoporosis: focus on its pharmacological properties]. Clinical calcium, 2004, Volume: 14, Issue:10 Topics: Biomarkers; Bone and Bones; Bone Density; Bone Resorption; Female; Femoral Neck Fractures; Humans; Osteocalcin; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Spinal Fractures	2004
[SERM and quality of bone]. Clinical calcium, 2004, Volume: 14, Issue:10 Topics: Bone and Bones; Bone Density; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures	2004
[Which is the better choice, estrogen or SERMs in postmenopausal women?]. Clinical calcium, 2004, Volume: 14, Issue:10 Topics: Breast Neoplasms; Estrogen Replacement Therapy; Female; Hip Fractures; Hot Flashes; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk; Selective Estrogen Receptor Modulators; Spinal Fractures; Uterine Hemorrhage	2004
Skeletal and nonskeletal effects of raloxifene. Current osteoporosis reports, 2003, Volume: 1, Issue:3 Topics: Aged; Breast Neoplasms; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fractures, Spontaneous; Hip Fractures; Humans; Middle Aged; Osteoporosis, Postmenopausal; Prognosis; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Severity of Illness Index; Spinal Fractures; Treatment Outcome	2003
Anti-vertebral fracture efficacy of raloxifene: a meta-analysis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2006, Volume: 17, Issue:2 Topics: Bone Density Conservation Agents; Double-Blind Method; Female; Humans; Odds Ratio; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Spinal Fractures	2006
A rational approach to evidence gaps in the management of osteoporosis. The American journal of medicine, 2005, Volume: 118, Issue:11 Topics: Age Factors; Aged; Animals; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resorption; Case Management; Cohort Studies; Diphosphonates; Drug Therapy, Combination; Estrogens; Evidence-Based Medicine; Female; Follow-Up Studies; Fractures, Spontaneous; Health Surveys; Hip Fractures; Humans; Incidence; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Raloxifene Hydrochloride; Rats; Risk Assessment; Spinal Fractures; Time Factors	2005
[Selective estrogen receptor modulators (SERMs)]. Clinical calcium, 2006, Volume: 16, Issue:9 Topics: Breast Neoplasms; Female; Humans; Organ Specificity; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Spinal Fractures; Stroke	2006
[Drug treatment of postmenopausal osteoporosis. What's New in 2006]. Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:10 Pt 2 Topics: Absorptiometry, Photon; Adult; Age Factors; Aged; Aged, 80 and over; Alendronate; Body Mass Index; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Female; Femoral Fractures; Follow-Up Studies; Fractures, Bone; Humans; Middle Aged; Organometallic Compounds; Osteoporosis, Postmenopausal; Practice Guidelines as Topic; Raloxifene Hydrochloride; Risk Factors; Spinal Fractures; Tablets; Teriparatide; Thiophenes; Time Factors	2006
[First choice drug for treatment of osteoporosis and the strategic points for choice of drugs]. Nihon rinsho. Japanese journal of clinical medicine, 2007, Nov-28, Volume: 65 Suppl 9 Topics: Bone Density; Bone Density Conservation Agents; Calcium; Cholecalciferol; Diphosphonates; Evidence-Based Medicine; Femoral Neck Fractures; Humans; Meta-Analysis as Topic; Osteoporosis; Practice Guidelines as Topic; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Spinal Fractures	2007
[Evidence of raloxifene on postmenopausal osteoporosis]. Nihon rinsho. Japanese journal of clinical medicine, 2007, Nov-28, Volume: 65 Suppl 9 Topics: Bone and Bones; Bone Density Conservation Agents; Breast Neoplasms; Evidence-Based Medicine; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Selective Estrogen Receptor Modulators; Spinal Fractures	2007
[Osteoporosis in the elderly--diagnosis and treatment]. MMW Fortschritte der Medizin, 2005, Feb-17, Volume: 147, Issue:7 Topics: Accidental Falls; Age Factors; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Calcium; Diphosphonates; Etidronic Acid; Exercise; Female; Hip Fractures; Humans; Male; Osteoporosis; Osteoporosis, Postmenopausal; Practice Guidelines as Topic; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors; Sex Factors; Spinal Fractures; Vitamin D	2005
Raloxifene. Not better than estrogen. Canadian family physician Medecin de famille canadien, 2000, Volume: 46 Topics: Aged; Estrogen Replacement Therapy; Female; Fractures, Spontaneous; Humans; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures	2000
[Treatment of osteoporosis: overview]. Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60 Suppl 3 Topics: Bone Density; Clinical Trials as Topic; Diphosphonates; Estrogen Replacement Therapy; Evidence-Based Medicine; Femoral Neck Fractures; Fractures, Stress; Humans; Osteoporosis; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Spinal Fractures	2002
[Drugs in development for the treatment of osteoporosis:Raloxifene]. Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60 Suppl 3 Topics: Bone Density; Bone Remodeling; Estrogen Antagonists; Female; Fractures, Stress; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures	2002

Trials

36 trial(s) available for raloxifene hydrochloride and Hangman Fracture

Article	Year
Effect of Bone Resorption Inhibitors on Serum Cholesterol Level and Fracture Risk in Osteoporosis: Randomized Comparative Study Between Minodronic Acid and Raloxifene. Calcified tissue international, 2023, Volume: 112, Issue:4 Topics: Aged; Bone Density; Bone Density Conservation Agents; Cholesterol; Female; Fractures, Bone; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Prospective Studies; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures	2023
Risk factors for incident vertebral fractures in osteoporosis pharmacotherapy: a 2-year, prospective, observational study. Journal of bone and mineral metabolism, 2021, Volume: 39, Issue:4 Topics: Accidental Falls; Aged; Biomarkers; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Multivariate Analysis; Osteoporosis; Prevalence; Prospective Studies; Raloxifene Hydrochloride; Risk Factors; Spinal Fractures	2021
Study design of multi-center, open-label randomized controlled, head-to-head trial comparing minodronic acid and raloxifene: Japanese Osteoporosis Intervention Trial (JOINT)-04. Journal of bone and mineral metabolism, 2019, Volume: 37, Issue:3 Topics: Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Incidence; Osteoporotic Fractures; Raloxifene Hydrochloride; Sample Size; Spinal Fractures	2019
An evaluation of the Fracture Risk Assessment Tool (FRAX®) as an indicator of treatment efficacy: the effects of bazedoxifene and raloxifene on vertebral, nonvertebral, and all clinical fractures as a function of baseline fracture risk assessed by FRAX®. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2013, Volume: 24, Issue:10 Topics: Aged; Aged, 80 and over; Algorithms; Bone Density; Bone Density Conservation Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Indoles; Kaplan-Meier Estimate; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Raloxifene Hydrochloride; Risk Assessment; Spinal Fractures; Treatment Outcome	2013
Cross-geographic region differences in quality of life in women with and without vertebral fracture. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2009, Volume: 20, Issue:10 Topics: Aged; Body Mass Index; Bone Density Conservation Agents; Epidemiologic Methods; Female; Humans; Indoles; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Psychometrics; Quality of Life; Raloxifene Hydrochloride; Spinal Fractures	2009
Teriparatide and raloxifene reduce the risk of new adjacent vertebral fractures in postmenopausal women with osteoporosis. Results from two randomized controlled trials. The Journal of bone and joint surgery. American volume, 2009, Volume: 91, Issue:6 Topics: Aged; Bone Density; Bone Density Conservation Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Fractures, Spontaneous; Humans; Incidence; Middle Aged; Osteoporosis, Postmenopausal; Prospective Studies; Raloxifene Hydrochloride; Reference Values; Risk Assessment; Severity of Illness Index; Spinal Fractures; Teriparatide; Treatment Outcome	2009
Benefits and risks of raloxifene by vertebral fracture status. Current medical research and opinion, 2010, Volume: 26, Issue:1 Topics: Aged; Bone Density Conservation Agents; Double-Blind Method; Female; Humans; Incidence; Middle Aged; Osteoporosis; Placebos; Raloxifene Hydrochloride; Spinal Fractures; Treatment Outcome	2010
Back pain during different sequential treatment regimens of teriparatide: results from EUROFORS. Current medical research and opinion, 2010, Volume: 26, Issue:8 Topics: Aged; Back Pain; Bone Density Conservation Agents; Calcium; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Pain Measurement; Raloxifene Hydrochloride; Spinal Fractures; Teriparatide; Treatment Outcome; Vitamin D	2010
Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. The Journal of clinical endocrinology and metabolism, 2002, Volume: 87, Issue:8 Topics: Aged; Bone and Bones; Bone Density; Estrogen Antagonists; Female; Follow-Up Studies; Humans; Incidence; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Risk Factors; Spinal Fractures; Treatment Outcome	2002
Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2002, Volume: 13, Issue:11 Topics: Aged; Bone Density; Dose-Response Relationship, Drug; Double-Blind Method; Female; Femur Neck; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Radiography; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Severity of Illness Index; Spinal Fractures	2002
Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial. Bone, 2003, Volume: 33, Issue:3 Topics: Aged; Bone Density; Bone Diseases, Metabolic; Estrogen Antagonists; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Risk Factors; Risk Reduction Behavior; Spinal Fractures; Treatment Outcome	2003
Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone, 2003, Volume: 33, Issue:4 Topics: Aged; Bone Density; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Recurrence; Risk Factors; Spinal Fractures	2003
Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. Bone, 2004, Volume: 34, Issue:2 Topics: Aged; Alkaline Phosphatase; Biomarkers; Collagen Type I; Estrogen Antagonists; Female; Humans; Logistic Models; Osteocalcin; Osteoporosis, Postmenopausal; Peptide Fragments; Procollagen; Raloxifene Hydrochloride; Risk Factors; Spinal Fractures	2004
Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2004, Volume: 19, Issue:3 Topics: Aged; Biomarkers; Bone Density; Bone Remodeling; Female; Femur Neck; Humans; Middle Aged; Osteoporosis; Prevalence; Radiography; Raloxifene Hydrochloride; Risk Factors; Spinal Fractures	2004
Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2004, Volume: 19, Issue:5 Topics: Analysis of Variance; Bone Density; Evaluation Studies as Topic; Humans; Lumbar Vertebrae; Osteoporosis, Postmenopausal; Prospective Studies; Radiography; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Spinal Fractures; Treatment Outcome; Triglycerides	2004
Raloxifene reduces risk of vertebral fractures [corrected] in postmenopausal women regardless of prior hormone therapy. The Journal of family practice, 2004, Volume: 53, Issue:10 Topics: Adult; Aged; Bone Density; Breast Neoplasms; Cardiovascular Diseases; Cerebrovascular Disorders; Estrogen Replacement Therapy; Female; Humans; Logistic Models; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Spinal Fractures	2004
Impact of incident vertebral fractures on health related quality of life (HRQOL) in postmenopausal women with prevalent vertebral fractures. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2005, Volume: 16, Issue:8 Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Double-Blind Method; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Quality of Life; Raloxifene Hydrochloride; Spinal Fractures	2005
[SERM & bone metabolism: protective effects of SERM against fracture risk and its long-term beneficial effects]. Clinical calcium, 2004, Volume: 14, Issue:10 Topics: Bone Density; Elbow; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk; Risk Assessment; Selective Estrogen Receptor Modulators; Spinal Fractures; Time Factors	2004
Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2005, Volume: 16, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Computer Simulation; Cost-Benefit Analysis; Estrogen Antagonists; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Quality of Life; Raloxifene Hydrochloride; Risk Factors; Spinal Fractures; Treatment Outcome; United Kingdom	2005
Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. The American journal of psychiatry, 2005, Volume: 162, Issue:4 Topics: Aged; Alzheimer Disease; Cognition Disorders; Comorbidity; Dementia; Female; Geriatric Assessment; Humans; Osteoporosis, Postmenopausal; Placebos; Psychiatric Status Rating Scales; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators; Severity of Illness Index; Spinal Fractures; Treatment Outcome	2005
Vitamin D insufficiency does not affect bone mineral density response to raloxifene. The Journal of clinical endocrinology and metabolism, 2005, Volume: 90, Issue:8 Topics: Aged; Bone Density; Drug Interactions; Estrogen Antagonists; Humans; Incidence; Middle Aged; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; Spinal Fractures; Vitamin D; Vitamin D Deficiency	2005
Raloxifene and colorectal cancer. Journal of women's health (2002), 2005, Volume: 14, Issue:4 Topics: Aged; Bone Density; Colorectal Neoplasms; Double-Blind Method; Estrogen Receptor Modulators; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Proportional Hazards Models; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Spinal Fractures; Time Factors; United States	2005
The effect of raloxifene therapy on the risk of new clinical vertebral fractures at three and six months: a secondary analysis of the MORE trial. Current medical research and opinion, 2005, Volume: 21, Issue:12 Topics: Aged; Double-Blind Method; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Reduction Behavior; Selective Estrogen Receptor Modulators; Spinal Fractures; Treatment Outcome	2005
Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. The New England journal of medicine, 2006, Jul-13, Volume: 355, Issue:2 Topics: Aged; Breast Neoplasms; Coronary Disease; Double-Blind Method; Female; Humans; Middle Aged; Postmenopause; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Spinal Fractures; Stroke; Thromboembolism	2006
Effects of raloxifene on fracture risk in postmenopausal women: the Raloxifene Use for the Heart Trial. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2008, Volume: 23, Issue:1 Topics: Aged; Coronary Disease; Double-Blind Method; Female; Fractures, Bone; Humans; Incidence; Middle Aged; Postmenopause; Raloxifene Hydrochloride; Risk; Spinal Fractures	2008
The effect of raloxifene treatment in postmenopausal women with CKD. Journal of the American Society of Nephrology : JASN, 2008, Volume: 19, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Female; Humans; Kidney Failure, Chronic; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Spinal Fractures	2008
Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1998, Volume: 13, Issue:11 Topics: Aged; Analysis of Variance; Biomarkers; Bone Density; Chi-Square Distribution; Double-Blind Method; Estrogen Antagonists; Female; Humans; Lipids; Middle Aged; Osteoporosis, Postmenopausal; Piperidines; Prospective Studies; Raloxifene Hydrochloride; Spinal Fractures	1998
Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA, 1999, Aug-18, Volume: 282, Issue:7 Topics: Adult; Aged; Bone Density; Estrogens; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Piperidines; Radiography; Raloxifene Hydrochloride; Risk; Spinal Fractures	1999
[Effects of raloxifene on bone loss and fracture risk in the menopausal woman]. Contraception, fertilite, sexualite (1992), 1999, Volume: 27, Issue:12 Topics: Aged; Bone Density; Female; Humans; Lipids; Menopause; Middle Aged; Osteoporosis, Postmenopausal; Placebos; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures	1999
Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2000, Volume: 15, Issue:7 Topics: Aged; Bone Density; Emotions; Estrogen Antagonists; Female; Health Status; Humans; Middle Aged; Osteoporosis, Postmenopausal; Pain; Postmenopause; Quality of Life; Raloxifene Hydrochloride; Spinal Fractures	2000
Can the prophylactic use of raloxifene, a selective estrogen-receptor modulator, prevent bone mineral loss and fractures in women with diagnosed osteoporosis or vertebral fractures? The Western journal of medicine, 2000, Volume: 173, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Bone Density; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Spinal Fractures; Treatment Outcome	2000
Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2002, Volume: 17, Issue:1 Topics: Aged; Bone Density; Female; Femur Neck; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Spinal Fractures; Time Factors	2002
Serum estradiol level and risk of breast cancer during treatment with raloxifene. JAMA, 2002, Jan-09, Volume: 287, Issue:2 Topics: Aged; Breast Neoplasms; Estradiol; Female; Hot Flashes; Humans; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk; Selective Estrogen Receptor Modulators; Spinal Fractures; Venous Thrombosis	2002
Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2001, Volume: 12, Issue:11 Topics: Alkaline Phosphatase; Biomarkers; Bone Remodeling; Chi-Square Distribution; Collagen; Enzyme-Linked Immunosorbent Assay; Estrogen Antagonists; Female; Humans; Logistic Models; Multivariate Analysis; Osteocalcin; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors; Spinal Fractures	2001
Bone histomorphometric and biochemical marker results of a 2-year placebo-controlled trial of raloxifene in postmenopausal women. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2002, Volume: 17, Issue:2 Topics: Aged; Biopsy; Bone Density; Bone Resorption; Double-Blind Method; Estrogen Antagonists; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures	2002
Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Archives of internal medicine, 2002, May-27, Volume: 162, Issue:10 Topics: Aged; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Incidence; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Recurrence; Risk; Selective Estrogen Receptor Modulators; Spinal Fractures; Time Factors	2002

Other Studies

35 other study(ies) available for raloxifene hydrochloride and Hangman Fracture

Article	Year
Effect of follow-up raloxifene therapy after denosumab discontinuation in postmenopausal women. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2022, Volume: 33, Issue:7 Topics: Bone Density; Bone Density Conservation Agents; Denosumab; Female; Follow-Up Studies; Humans; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Spinal Fractures	2022
Real-world effectiveness of osteoporosis therapies for fracture reduction in post-menopausal women. Archives of osteoporosis, 2018, Mar-21, Volume: 13, Issue:1 Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Denosumab; Female; Humans; Incidence; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Raloxifene Hydrochloride; Spinal Fractures; Teriparatide; United States; Zoledronic Acid	2018
Efficacy, effectiveness and side effects of medications used to prevent fractures. Journal of internal medicine, 2015, Volume: 277, Issue:6 Topics: Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Calcium Compounds; Denosumab; Diphosphonates; Etidronic Acid; Evidence-Based Medicine; Hip Fractures; Humans; Ibandronic Acid; Imidazoles; Osteoporosis; Osteoporotic Fractures; Raloxifene Hydrochloride; Risedronic Acid; Risk Assessment; Spinal Fractures; Teriparatide; Thiophenes; Treatment Outcome; Vitamin D; Zoledronic Acid	2015
Is raloxifene associated with lower risk of mortality in postmenopausal women with vertebral fractures after vertebroplasty?: a hospital-based analysis. BMC musculoskeletal disorders, 2015, Aug-19, Volume: 16 Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Female; Follow-Up Studies; Humans; Middle Aged; Mortality; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Postmenopause; Raloxifene Hydrochloride; Retrospective Studies; Risk Factors; Spinal Fractures; Vertebroplasty	2015
Initiation of anti-osteoporotic therapy in patients with recent fractures: a nationwide analysis of prescription rates and persistence. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2009, Volume: 20, Issue:2 Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Drug Administration Schedule; Drug Prescriptions; Female; Fractures, Bone; Hip Fractures; Humans; Male; Middle Aged; Patient Compliance; Practice Patterns, Physicians'; Raloxifene Hydrochloride; Sex Distribution; Spinal Fractures; Treatment Outcome	2009
Raloxifene and risk for stroke based on the framingham stroke risk score. The American journal of medicine, 2009, Volume: 122, Issue:8 Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Spinal Fractures; Stroke	2009
Another selective estrogen-receptor modulator for osteoporosis. The New England journal of medicine, 2010, Feb-25, Volume: 362, Issue:8 Topics: Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Coronary Disease; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Pyrrolidines; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Spinal Fractures; Stroke; Tamoxifen; Tetrahydronaphthalenes; Venous Thromboembolism	2010
Latest innovation in the treatment of osteoporosis: SERMs and the role of parathyroid hormone. Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2004, Volume: 87 Suppl 3 Topics: Bone Density; Bone Density Conservation Agents; Clinical Trials as Topic; Estrogen Antagonists; Female; Humans; Osteoporosis, Postmenopausal; Parathyroid Hormone; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures; Teriparatide; Therapies, Investigational; Treatment Outcome	2004
[Weeks of pain, vertebral body fractures during sleep, invalidism. Save your osteoporosis patients from this fate]. MMW Fortschritte der Medizin, 2002, Oct-31, Volume: 144, Issue:44 Topics: Activities of Daily Living; Age Factors; Alendronate; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Disabled Persons; Etidronic Acid; Female; Femoral Fractures; Humans; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Pain; Raloxifene Hydrochloride; Risedronic Acid; Sex Factors; Spinal Fractures	2002
[SERM for early osteoporosis therapy. Risk for first spinal fracture reduced to half]. MMW Fortschritte der Medizin, 2003, May-29, Volume: 145, Issue:22 Topics: Breast Neoplasms; Clinical Trials as Topic; Estrogen Antagonists; Humans; Incidence; Osteoporosis, Postmenopausal; Placebos; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Spinal Fractures; Time Factors	2003
[Osteoporosis therapy compared. More solid bones with bisphosphonates]. MMW Fortschritte der Medizin, 2003, Aug-07, Volume: 145, Issue:31-32 Topics: Alendronate; Bone Density; Clinical Trials as Topic; Diphosphonates; Female; Fractures, Bone; Humans; Meta-Analysis as Topic; Middle Aged; Multicenter Studies as Topic; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures; Time Factors	2003
Safety profile of raloxifene as used in general practice in England: results of a prescription-event monitoring study. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2005, Volume: 16, Issue:5 Topics: Adverse Drug Reaction Reporting Systems; Aged; Drug Interactions; England; Family Practice; Female; Flushing; Humans; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures	2005
Comparison of fracture, cardiovascular event, and breast cancer rates at 3 years in postmenopausal women with osteoporosis. Journal of the American Geriatrics Society, 2004, Volume: 52, Issue:9 Topics: Age Distribution; Aged; Bone Density; Breast Neoplasms; Calcium; Cardiovascular Diseases; Female; Global Health; Hip Fractures; Humans; Incidence; Multicenter Studies as Topic; Osteoporosis, Postmenopausal; Patient Selection; Population Surveillance; Prevalence; Prospective Studies; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Spinal Fractures; Vitamin D	2004
[Delaying degeneration or promoting regeneration. 2 successful strategies in osteoporosis]. MMW Fortschritte der Medizin, 2004, Mar-04, Volume: 146, Issue:10 Topics: Aged; Bone Density; Clinical Trials as Topic; Female; Fractures, Spontaneous; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures; Teriparatide	2004
[Risk of osteoporosis in postmenopausal women. When is bone density measurement indicated?]. MMW Fortschritte der Medizin, 2004, May-20, Volume: 146, Issue:21 Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Etidronic Acid; Evidence-Based Medicine; Fractures, Spontaneous; Humans; Middle Aged; Osteoporosis, Postmenopausal; Practice Guidelines as Topic; Raloxifene Hydrochloride; Risedronic Acid; Selective Estrogen Receptor Modulators; Spinal Fractures	2004
Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. PharmacoEconomics, 2004, Volume: 22, Issue:17 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Breast Neoplasms; Computer Simulation; Cost-Benefit Analysis; Female; Humans; Middle Aged; Models, Economic; Osteoporosis; Quality-Adjusted Life Years; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Spinal Fractures; Sweden; Treatment Outcome	2004
[Update 2004. Osteoporosis--management--current status]. Krankenpflege Journal, 2004, Volume: 42, Issue:7-10 Topics: Aged; Aged, 80 and over; Alendronate; Calcium, Dietary; Cross-Sectional Studies; Etidronic Acid; Female; Fractures, Spontaneous; Germany; Health Surveys; Hip Fractures; Humans; Male; Middle Aged; Osteoporosis; Practice Guidelines as Topic; Raloxifene Hydrochloride; Risedronic Acid; Spinal Fractures; Vitamin D	2004
Risk-benefit profiles of raloxifene for women. The New England journal of medicine, 2006, Jul-13, Volume: 355, Issue:2 Topics: Aged; Breast Neoplasms; Coronary Disease; Female; Humans; Middle Aged; Postmenopause; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators; Spinal Fractures	2006
Lessons from RUTH. Climacteric : the journal of the International Menopause Society, 2006, Volume: 9, Issue:5 Topics: Breast Neoplasms; Coronary Artery Disease; Female; Humans; Postmenopause; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Spinal Fractures; Thromboembolism	2006
[Osteoporosis priority: Reduce the number of fractures]. Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:10 Pt 2 Topics: Absorptiometry, Photon; Age Factors; Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Femoral Fractures; Fractures, Bone; Humans; Male; Middle Aged; Organometallic Compounds; Osteoporosis; Osteoporosis, Postmenopausal; Prospective Studies; Raloxifene Hydrochloride; Risk Factors; Spinal Fractures; Teriparatide; Thiophenes; Time Factors	2006
Do estrogen or selective estrogen receptor modulators improve quality of life for women with postmenopausal osteoporosis? Current osteoporosis reports, 2007, Volume: 5, Issue:1 Topics: Aged; Aged, 80 and over; Back Pain; Estrogens; Fatigue; Female; Fractures, Spontaneous; Hip Fractures; Humans; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Prevalence; Quality of Life; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Spinal Fractures; Tamoxifen; United States	2007
Raloxifene reduces spinal fractures postmenopausally. Lancet (London, England), 1999, Aug-21, Volume: 354, Issue:9179 Topics: Adult; Aged; Aged, 80 and over; Estrogens; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Spinal Fractures	1999
Fewer fractures with raloxifene. Health news (Waltham, Mass.), 1999, Oct-01, Volume: 5, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures	1999
[Raloxifene (Celvista, Evista)]. Revue medicale de Bruxelles, 2000, Volume: 21, Issue:1 Topics: Arteriosclerosis; Bone and Bones; Breast Neoplasms; Controlled Clinical Trials as Topic; Endometrium; Female; Fractures, Bone; Heart Diseases; Hip Fractures; Humans; Middle Aged; Osteoporosis, Postmenopausal; Placebos; Prospective Studies; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Spinal Fractures; Thromboembolism; Uterine Hemorrhage	2000
Vertebroplasty: an opportunity to do something really good for patients. Spine, 2000, May-01, Volume: 25, Issue:9 Topics: Alendronate; Bone Cements; Calcitonin; Humans; Osteoporosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures	2000
Raloxifene and risk of vertebral fracture in postmenopausal women. JAMA, 2000, May-03, Volume: 283, Issue:17 Topics: Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Spinal Fractures	2000
Bone structure in patients with low bone mineral density with or without vertebral fractures. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2000, Volume: 15, Issue:7 Topics: Age Factors; Aged; Bone and Bones; Bone Density; Estrogen Antagonists; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Radiography; Raloxifene Hydrochloride; Regression Analysis; Spinal Fractures	2000
Reduction of vertebral fracture risk with raloxifene. The Journal of family practice, 1999, Volume: 48, Issue:11 Topics: Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Spinal Fractures	1999
Pharmacological interventions for the prevention of vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: does site-specificity exist? Bone, 2000, Volume: 27, Issue:6 Topics: Aged; Alendronate; Calcitriol; Calcium Channel Agonists; Calcium Channel Blockers; Estrogen Antagonists; Etidronic Acid; Female; Hip Fractures; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Spinal Fractures	2000
Raloxifene and prevention of vertebral fracture (cont'd): mainly when oestrogen is contraindicated. Prescrire international, 2000, Volume: 9, Issue:50 Topics: Breast Neoplasms; Clinical Trials as Topic; Contraindications; Diabetes Mellitus; Estrogen Replacement Therapy; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Spinal Fractures; Thromboembolism; Uterine Neoplasms	2000
The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis: results from the Multiple Outcomes of Raloxifene Evaluation Study. Arthritis and rheumatism, 2001, Volume: 44, Issue:11 Topics: Aged; Aged, 80 and over; Female; Follow-Up Studies; Humans; Middle Aged; Osteoporosis, Postmenopausal; Quality of Life; Radiography; Raloxifene Hydrochloride; Severity of Illness Index; Sickness Impact Profile; Spinal Fractures	2001
Does raloxifene reduce risk of vertebral fractures? Is this another, brighter way to treat osteoporosis? Canadian family physician Medecin de famille canadien, 2001, Volume: 47 Topics: Adult; Aged; Aged, 80 and over; Family Practice; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Patient Selection; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Spinal Fractures	2001
Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2002, Volume: 17, Issue:1 Topics: Aged; Bone Density; Bone Remodeling; Female; Humans; Middle Aged; Models, Biological; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Spinal Fractures	2002
[Economic aspects of osteoporosis therapy. What does a prevented fracture cost?]. MMW Fortschritte der Medizin, 2001, Nov-22, Volume: 143, Issue:47 Topics: Aged; Alendronate; Cost-Benefit Analysis; Etidronic Acid; Female; Fractures, Spontaneous; Germany; Humans; National Health Programs; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Spinal Fractures	2001
Raloxifene remains an option. Canadian family physician Medecin de famille canadien, 2002, Volume: 48 Topics: Aged; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures	2002